Premier Fund Managers Ltd Takes Position in Repligen Co. (NASDAQ:RGEN)

Premier Fund Managers Ltd acquired a new position in shares of Repligen Co. (NASDAQ:RGEN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,113 shares of the biotechnology company’s stock, valued at approximately $592,000.

A number of other institutional investors have also recently bought and sold shares of RGEN. Charles Schwab Investment Management Inc. increased its holdings in shares of Repligen by 1.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 363,379 shares of the biotechnology company’s stock worth $54,078,000 after acquiring an additional 5,478 shares in the last quarter. Cerity Partners LLC increased its stake in Repligen by 90.0% during the 3rd quarter. Cerity Partners LLC now owns 5,541 shares of the biotechnology company’s stock worth $825,000 after purchasing an additional 2,625 shares in the last quarter. Bank of Montreal Can raised its holdings in Repligen by 34.9% during the 3rd quarter. Bank of Montreal Can now owns 49,568 shares of the biotechnology company’s stock worth $7,233,000 after buying an additional 12,816 shares during the period. Townsquare Capital LLC lifted its stake in Repligen by 5.0% in the third quarter. Townsquare Capital LLC now owns 14,106 shares of the biotechnology company’s stock valued at $2,099,000 after buying an additional 670 shares in the last quarter. Finally, Glenmede Trust Co. NA boosted its holdings in shares of Repligen by 13.4% in the third quarter. Glenmede Trust Co. NA now owns 6,158 shares of the biotechnology company’s stock valued at $916,000 after buying an additional 728 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Insider Activity at Repligen

In related news, Director Margaret Pax purchased 250 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.20% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on RGEN shares. Canaccord Genuity Group boosted their price objective on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Evercore ISI assumed coverage on Repligen in a report on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price objective for the company. TD Cowen initiated coverage on Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. Finally, Canaccord Genuity Group assumed coverage on Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, Repligen has a consensus rating of “Hold” and an average target price of $178.64.

Repligen Stock Performance

Shares of RGEN stock opened at $133.41 on Friday. The company has a fifty day moving average price of $154.21 and a two-hundred day moving average price of $148.14. Repligen Co. has a one year low of $113.50 and a one year high of $184.98. The stock has a market cap of $7.49 billion, a P/E ratio of -261.59, a P/E/G ratio of 4.54 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.03. The business had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, equities analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.